Sorbent Therapeutics' CLP1001 Improves Heart Failure Symptoms In Phase 2 ... MarketWatch (press release) In the study of 111 heart failure patients with chronic kidney disease, CLP1001 demonstrated improvement in heart failure symptoms as compared to placebo. Data from the randomized, double-blind Phase 2a study were presented in an oral session at the ... |
